Comparison between Duroflex IPO and Integris Medtech IPO.
Duroflex IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Integris Medtech IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Duroflex IPO is up to ₹0.00 Cr whereas the issue size of the Integris Medtech IPO is up to ₹0.00 Cr. The final issue price of Duroflex IPO is and of Integris Medtech IPO is .
| Duroflex IPO | Integris Medtech IPO | |
|---|---|---|
| Face Value | ₹1 per share | ₹1 per share |
| Issue Price (Lower) | ||
| Issue Price (Upper) | ||
| Issue Price (Final) | ||
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | ||
| Fresh Issue Size | 0 shares | 0 shares |
| Fresh Issue Size (Amount) | up to ₹183.60 Cr | up to ₹925.00 Cr |
| OFS Issue Size | 2,25,64,569 shares | 2,16,74,531 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 0 shares | 0 shares |
| Issue Size Total (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
Duroflex IPO opens on , while Integris Medtech IPO opens on . The closing date of Duroflex IPO and Integris Medtech IPO is , and , respectively.
Duroflex IPO P/E ratio is , as compared to Integris Medtech IPO P/E ratio of .
| Duroflex IPO | Integris Medtech IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)Duroflex Ltd.'s revenue increased by 4% and profit after tax (PAT) rose by 321% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated Consolidated)Integris Medtech Ltd.'s revenue increased by 24% and profit after tax (PAT) rose by 1547% between the financial year ending with March 31, 2025 and March 31, 2024.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 66.10 | 83.24 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 12.72% | 5.35% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 14.90% | 14.51% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹6.52 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 11.82% | 1.48% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Duroflex IPO Retail Individual Investors (RII) are offered 0 shares while in Integris Medtech IPO retail investors are offered 0 shares. Qualified Institutional Buyers (QIB) are offered 0 shares in Duroflex IPO and 0 shares in Integris Medtech IPO.
| Duroflex IPO | Integris Medtech IPO | |
|---|---|---|
| Anchor Investor Reservation | 0 shares | 0 shares |
| Market Maker Reservation | 0 shares | 0 shares |
| QIB | 0 shares | 0 shares |
| NII | 0 shares | 0 shares |
| RII | 0 shares | 0 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 0 shares | 0 shares |
Duroflex IPO subscribed in total, whereas Integris Medtech IPO subscribed .
